

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No. 7,612,201 ) Serial No. 10/536,899  
 )  
Inventor(s): Mandy Christine Bcswick ) Filed: December 18, 2003  
 )  
Issue Date: November 3, 2009 ) Attorney Docket No. 010180.00031

For: PYRAZOLE COMPOUNDS

**REQUEST FOR CERTIFICATE OF CORRECTION**

U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop: Certificate of Correction Branch  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, this is a request for the issuance of a Certificate of Correction in the above-identified patent. A copy of PTO Form 1050 is appended. The complete Certificate of Correction involves 1 page.

The mistakes identified in the appended Form occurred through no fault of the Applicants, as clearly disclosed by the records of the application, which matured into this patent. Enclosed for your convenience is the amendment filed April 27, 2009.

Issuance of the Certificate of Correction containing the corrections is respectfully requested. Since these changes are necessitated through no fault of the Applicants, no fee is believed to be associated with this request. Nonetheless, should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Dated: April 26, 2010  
Banner & Witcoff, Ltd  
1100 13<sup>th</sup> Street, N.W., Suite 1200  
Washington, D.C. 20005-4051  
(202) 824-3000

By: /Susan A. Wolff/  
Susan A Wolff  
Registration No. 33,568

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO.: 7,612,201

DATED: November 3, 2009

INVENTOR(S): Mandy Christine Beswick et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Column 76, Claim 4, Line 28:

Please remove "(C<sub>1</sub>-C<sub>6</sub>)" and insert -- (C<sub>1</sub>-C<sub>6</sub>) --.

In Column 76, Claim 4, Line 32:

Please remove "-SO<sub>2</sub>NH<sub>2</sub>" and insert -- -SO<sub>2</sub>NH<sub>2</sub> --.

In Column 78, Claim 7, Line 13:

Please remove "by chlоро or" and insert --by chloro or--.

In Column 78, Claim 7, Line 29:

Please remove "NR<sup>A</sup>" between the words "represents" and "wherein".

Mailing Address of Sender:

U.S. PAT. NO.  
7,612,201

Banner & Witcoff Ltd.  
1100 13<sup>th</sup> Street, N.W., Suite 1200  
Washington, DC 20005-4051

No. of add'l copies  
@ \$0.50 per page

□

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5221742
<b>Application Number:</b>	10536899
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6636
<b>Title of Invention:</b>	Pyrazole compounds
<b>First Named Inventor/Applicant Name:</b>	Christine Beswick
<b>Customer Number:</b>	22907
<b>Filer:</b>	Susan A. Wolff/lynn hudgins
<b>Filer Authorized By:</b>	Susan A. Wolff
<b>Attorney Docket Number:</b>	010180.00031
<b>Receipt Date:</b>	27-APR-2009
<b>Filing Date:</b>	06-JAN-2006
<b>Time Stamp:</b>	12:18:09
<b>Application Type:</b>	U.S. National Stage under 35 USC 3/1

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 130
RAM confirmation Number	9316
Deposit Account	190733
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment After Final	2FinAmd.pdf	172391 9096106544 and 153863814611 8cc	no	8

### Warnings:

### Information:

2	Fee Worksheet (PTO-875)	fee-info.pdf	30086	no	2
			761504622342204986460871350621 82790		

### Warnings:

### Information:

Total Files Size (in bytes): 202477

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

#### New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

#### National Stage of an International Application Under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

#### New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

**PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ) Confirmation No.: 6636  
Mandy Christine BESWICK et al. )  
Serial No: 10/536,899 ) Group Art Unit: 1624  
Filed: January 6, 2006 )  
For: PYRAZOLE COMPOUNDS ) Examiner: Emily A. Bernhardt  
 ) Docket No. 010180.00031  
 )

**SECOND AMENDMENT AFTER FINAL REJECTION**

U.S. Patent and Trademark Office  
Customer Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

In response to the final Office Action dated January 21, 2009, for which the period for response is extended one month, please amend the instant application as follows:



**Amendment to the Claims** are reflected in the Listing of Claims, which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 7 of this paper.

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula (IA) or (IB) or a salt, or N-oxide, hydrate or solvate thereof:



wherein

Ar is a 2,4-dihydroxyphenyl group which is optionally further substituted in the 5-position;

R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, methyl, ethyl, n- or iso-propyl, hydroxyethyl, or benzyl;

ring A is a ring of formula (IIA)



wherein X represents N, and Y represents CH, O, S or NH.

wherein (i) a ring carbon is optionally substituted, and/or (ii) a ring nitrogen is optionally substituted by a group of formula -(Alk<sup>1</sup>)<sub>r</sub>-(Cyc)<sub>n</sub>-(Alk<sup>3</sup>)<sub>s</sub>-(Z)-(Alk<sup>2</sup>)-Q where

Alk<sup>1</sup>, Alk<sup>2</sup> and Alk<sup>3</sup> are optionally substituted C<sub>1</sub>-C<sub>3</sub> alkyl.

Cyc is an optionally substituted phenylene radical;

n, r and s are independently 0 or 1.

Z is -O-, -S-, -(C=O)-, -SO<sub>2</sub>-, -C(=O)O-, -OC(=O)-, -NR<sup>A</sup>-, -C(=O)NR<sup>A</sup>-,

-NR<sup>A</sup>C(=O)-, -SO<sub>2</sub>NR<sup>A</sup>-, or -NR<sup>A</sup>SO<sub>2</sub>- wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and

Q is hydrogen or an optionally substituted phenyl, pyridyl, furyl, thienyl, oxadiazolyl.

imidazolyl or morpholinyl-carbocyclic or heterocyclic radical; and  
wherein "optionally substituted" means substituted with up to four substituents, each of which is independently selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo, trifluoromethyl, trifluoromethoxy, nitro, nitrile, oxo, phenyl, -COOH, -COR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -CONHNH<sub>2</sub>; -CONHNHR<sup>A</sup>, -CONHNR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -CONHR<sup>A</sup>, SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCONH<sub>2</sub>, -OCONHR<sup>A</sup>, -OCONR<sup>A</sup>R<sup>B</sup>, -NHCOOR<sup>A</sup>, -NHCOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NHSO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, -NHCONHR<sup>B</sup>, -NR<sup>A</sup>CONIR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, and -NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>)alkyl group.

Claims 2-8 (Canceled)

9. (Previously Presented) A compound as claimed in claim 1 wherein R<sub>1</sub> and R<sub>2</sub> are each hydrogen.

Claims 10-12 (Canceled)

13. (Currently Amended) A compound as claimed in claim 9 wherein in the ring of formula (IIA), Y is -NR<sup>A</sup> - wherein R<sup>A</sup> is a radical of formula -(Alk<sup>1</sup>)-Q, wherein Alk<sup>1</sup> is a C<sub>1</sub>-C<sub>3</sub> alkylene radical and Q is optionally substituted phenyl, pyridyl, furyl, thieryl, oxadiazolyl, imidazolyl or morpholinyl, wherein optionally substituted means substituted with up to four substituents, each of which is independently selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo, trifluoromethyl, trifluoromethoxy, nitro, nitrile, oxo, phenyl, -COOH, -COR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -CONINH<sub>2</sub>, -CONINHR<sup>A</sup>, -CONINR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -CONIR<sup>A</sup>, SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCONH<sub>2</sub>, -OCONHR<sup>A</sup>, -OCONR<sup>A</sup>R<sup>B</sup>, -NHCOOR<sup>A</sup>, -NHCOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NHSO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, -NHCONHR<sup>B</sup>, -NR<sup>A</sup>CONIR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, and -NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>)alkyl group is defined as in claim 1.

14. (Canceled)

15. (Currently Amended) A compound as claimed in claim 9 wherein in the ring of formula (IIA), Y is -NR<sup>A</sup>- wherein R<sup>A</sup> is a radical of formula -(Alk<sup>1</sup>)<sub>p</sub>-(Cyc)<sub>r</sub>-(Alk<sup>3</sup>)<sub>m</sub>-(Z)-(Alk<sup>2</sup>)-Q wherein Alk<sup>1</sup>, Alk<sup>2</sup>, Alk<sup>3</sup>, Cyc, Z and Q are as defined in claim 1

Alk<sup>1</sup>, Alk<sup>2</sup> and Alk<sup>3</sup> are optionally substituted C<sub>1</sub>-C<sub>8</sub> alkyl,

Cyc is an optionally substituted phenylene radical;


Z is -O-, -S-, -(C=O)-, -SO-, -C(=O)O-, -OC(=O)-, -NR<sup>A</sup>-, -C(=O)NR<sup>A</sup>-,

-NR<sup>A</sup>C(=O)-, -SO<sub>2</sub>NR<sup>A</sup>-, or -NR<sup>A</sup>SO<sub>2</sub>- wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl, and


Q is an optionally substituted phenyl, pyridyl, furyl, thienyl, oxadiazolyl, imidazolyl, or morpholinyl wherein "optionally substituted" means substituted with up to four substituents, each of which is independently selected from (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)alkoxy, hydroxy, hydroxymethyl, mercapto, mercapto(C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)alkylthio, halo, trifluoromethyl, trifluoromethoxy, nitro, nitrile, oxo, phenyl, -COOH, -COOR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -CONHNH<sub>2</sub>, -CONINHR<sup>A</sup>, -CONHNR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -CONHR<sup>A</sup>, SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCONH<sub>2</sub>, -OCONHR<sup>A</sup>, -OCONR<sup>A</sup>R<sup>B</sup>, -NHCOR<sup>A</sup>, -NHOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NSO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, -NHCONINHR<sup>B</sup>, -NR<sup>A</sup>CONIIR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, and -NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>8</sub>)alkyl group.

16. (Canceled)

17. (Currently Amended) A compound of formula (IC) or (ID) or a salt, or N-oxide, hydrate or solvate thereof:



(IC)



(ID)

wherein R is hydrogen, an optional substituent chloro, bromo, or a phenylethyl group which is optionally substituted in the phenyl ring, and R<sub>2</sub>, m, r, s, Alk<sup>3</sup>, Z, Alk<sup>2</sup> and optionally substituted are as defined in claim 1

R<sub>2</sub> is independently hydrogen, methyl, ethyl, n- or iso-propyl, hydroxyethyl, or benzyl;

Alk<sup>2</sup> and Alk<sup>3</sup> are optionally substituted C<sub>1</sub>-C<sub>3</sub> alkyl;

m, r and s are independently 0 or 1,

Z is -O-, -S-, -(C=O)-, -SO<sub>2</sub>-, -(C=O)O-, -OC(=O)-, -NR<sup>A</sup>-, -C(=O)NR<sup>A</sup>-,

-NR<sup>A</sup>C(=O)-, -SO<sub>2</sub>NR<sup>A</sup>-, or -NR<sup>A</sup>SO<sub>2</sub>- wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and

Q is an optionally substituted phenyl, pyridyl, furyl, thienyl, oxadiazolyl, imidazolyl, or morpholinyl,

wherein "optionally substituted" means substituted with up to four substituents, each of which is independently selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo, trifluoromethyl,

trifluoromethoxy, nitro, nitrile, ovo, phenyl, -COOH, -COOR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -CONIINH<sub>2</sub>, -CONIINHR<sup>A</sup>, -CONINR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -CONIIR<sup>A</sup>, SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCO NH<sub>2</sub>, -OCO NH<sup>A</sup>, -OCO NR<sup>A</sup>R<sup>B</sup>, -NHCOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NHSO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, -NHCONHR<sup>B</sup>, -NR<sup>A</sup>CONHR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, and -NR<sup>C</sup>CONR<sup>A</sup>R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>2</sub>)alkyl group.


18. (Canceled)

19. (Canceled)

20. (Currently Amended) A compound as claimed in claim 17 wherein [[n]]<sub>01</sub> is 0, r is 1, and Z is -C(=O)NH-.

Claims 21 – 28 (Canceled)

29. (New) A compound of formula (IA) or (IB) or a salt, or N-oxide thereof:



wherein

Ar is a 2,4-dihydroxyphenyl group which further substituted in the 5-position by chloro or bromo; or by optionally substituted phenyl or C<sub>1</sub>-C<sub>6</sub> alkyl; or by a phenylethyl group which is optionally substituted in the phenyl ring thereof.

R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, methyl, ethyl, n- or iso-propyl, hydroxyethyl, or benzyl.

ring A is a ring of formula (IIA)



wherein X represents N, and Y represents wherein R<sup>A</sup> is a radical of formula -(Alk<sup>I</sup>)<sub>n</sub>-Q, wherein Alk<sup>I</sup> is a C<sub>1</sub>-C<sub>3</sub> alkylene radical and Q is optionally substituted phenyl, pyridyl, furyl, thienyl, oxadiazolyl, imidazolyl or morpholinyl, wherein optionally substituted means substituted with up to four substituents, each of which is independently selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo, trifluoromethyl, trifluoromethoxy, nitro, nitrile, oxo, phenyl, -COOH, -COOR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -CONHNH<sub>2</sub>, -CONHNHR<sup>A</sup>, -CONHNR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -CONHR<sup>A</sup>, SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCONH<sub>2</sub>, -OCONHR<sup>A</sup>, -OCONR<sup>A</sup>R<sup>B</sup>, -NHCOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NHSO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, -NHCONHR<sup>B</sup>, -NR<sup>A</sup>CONHR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, and -NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>)alkyl group.

**REMARKS/ARGUMENTS**

The office action of January 21, 2009 has been carefully reviewed and these remarks are responsive thereto. Reconsideration and allowance of the instant application are respectfully requested. Claims 1, 9, 13, 15, 17, 20 and 29 are pending in this application. Claims 2-8, 10-12, 14, 16, 18, 19, and 21-28 are canceled.

Applicants appreciate the Examiner's telephone discussion today regarding claim 28. Accordingly, claim 28 has been canceled and replaced with new independent claim 29.

Claims 17 and 20 stand rejected under 35 USC 112, second paragraph, as indefinite. Claim 17 has been amended to correct the recitation of R and include "Q." Claim 20 has been amended to recite "n" instead of "n." Withdrawal of this rejection is requested.

Claims 1-20, 22-24, and 26-27 stand rejected under 35 USC 112, first paragraph, as non-enabling for the term "solvates."

Solvates and hydrates have been deleted from the claims. Withdrawal of this rejection is requested.

Claims 13, 15, and 28 are objected to as improper form as being a multiple dependent claim. Claims 13 and 15 have been amended to recite definitions in each claim. Claim 28 has been rewritten as new independent claim 29. Withdrawal of this rejection is requested.

**CONCLUSION**

If any additional fees are required or if an overpayment is made, the Commissioner is authorized to debit or credit our Deposit Account No. 19-0733, accordingly.

All rejections having been addressed, applicants respectfully submit that the instant application is in condition for allowance, and respectfully solicit prompt notification of the same.

Respectfully submitted,

/Susan A. Wolffe/

Date: April 27, 2009

Susan A. Wolffe  
Reg. No. 33,568

1100 13<sup>th</sup> Street, N.W. Suite 1200  
Washington, D.C. 20005-4051  
Tel (202) 824-3000  
Fax (202) 824-3001